Multiple Myeloma

Active Biotech: FDA Grants Orphan Drug Designation for Tasquinimod for the Treatment of Multiple Myeloma

(Yahoo! Finance) Apr 12, 2017 - Active Biotech AB announces today that Active Biotech has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.

read article

Method May Help Myeloma Patients Avoid Painful Biopsies

(MIT News) Apr 4, 2017 - Engineers at MIT have devised a microfluidic technique to capture and count circulating plasma cells from small samples of blood. The technique, which relies on conventional blood draws, may provide patients with a less painful test for multiple myeloma.

read article

Chemo Plus Tx Tops Chemo Alone in Myeloma

(MedPage Today) Apr 5, 2017 - The combination of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) plus autologous stem cell transplantation (ASCT) prolonged progression-free, although not overall, survival, compared with RVD alone in patients with newly diagnosed multiple myeloma, a phase III, open-label study demonstrated.

read article (free registration required)

The Land of the Vikings May Hold the Cure For Cancer

(CNBC/Modern Medicine) Apr 6, 2017 - Sometimes, innovation that can change the world pops up in the most unimaginable places. That's the case in cancer research.

read article

Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting

(Morningstar) Apr 4, 2017 - Kite Pharma, Inc. today announced new data presentations from preclinical studies related to KITE-585, a fully human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell product candidate for the treatment of multiple myeloma (MM) at the American Association of Cancer Research (AACR) Annual Meeting in Washington D.C.

read article

Method May Help Myeloma Patients Avoid Painful Biopsies

(MIT News Office) Apr 4, 2017 - Engineers at MIT have devised a microfluidic technique to capture and count circulating plasma cells from small samples of blood. The technique, which relies on conventional blood draws, may provide patients with a less painful test for multiple myeloma.

read article

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma

(Amgen) Apr 4, 2017 - Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization to the European Medicines Agency (EMA) for XGEVA® (denosumab).

read corporate press release

Karyopharm Shakes Off Clinical Hold For Lead Cancer Med

(BioPharma Dive) Mar 30, 2017 - Karyopharm got the go-ahead on Thursday to continue several studies of its lead candidate less than a few weeks after regulators placed them on partial clinical hold — an update that indicated problems with the trials were administrative in nature.

read article

After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers

(NASDAQ) Mar 30, 2017 - Cellectar Biosciences, Inc., an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate (PDC) CLR 131 in patients with multiple myeloma and other hematologic malignancies.

read article

Better Outcomes with New Tx Option in Multiple Myeloma

(MedPage Today) Mar 28, 2017 - Novel therapies and combinations of agents for relapsed or refractory multiple myeloma (RRMM) have substantially increased overall response rates (ORR) over nearly two decades, eliciting robust responses even among those who received multiple lines of therapy, according to a literature review.

read article (free registration required)

Soon-Shiong’s Promotion Of ‘Breakthrough’ Cancer Therapy Raises Questions

(STAT) Mar 27, 2017 - The emotional video tells of a patient with blood cancer who tries an experimental therapy involving “natural killer” cells. “NEW BREAKTHROUGH HELPS PATIENTS KILL CANCER” the banner headline declares as the patient, wiping away tears, covers her face with her hands and murmurs, “It’s really good news.”

read article

NICE Set to Reject Janssen's Darzalex for Multiple Myeloma

(PharmaTimes [UK]) Mar 17, 2017 - Janssen said it is extremely concerned that the National Institute for Health and Care Excellence (NICE) has not recommended Darzalex for treatment of relapsed and refractory multiple myeloma in adults in preliminary guidelines.

read article

FDA Puts Partial Hold On Karyopharm's Cancer Drug

(BioPharma Dive) Mar 12, 2017 - Karyopharm Therapeutics said March 10 it has responded to written notice from the Food and Drug Administration that clinical trials for the pharma’s oncology drug selinexor (KPT-330) have been placed on partial clinical hold.

read article

Mayo Clinic Researchers Identify Therapy That Shrinks Tumors In Patients With Multiple Myeloma

(Mayo Clinic) Mar 8, 2017 - Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma.

read article

Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop

(Amgen) Mar 3, 2017 - Late-breaking presentation to show overall survival benefit of KYPROLIS compared to Velcade® (bortezomib) in relapsed or refractory multiple myeloma patients; first-and-only head-to-head study comparing proteasome inhibitors to demonstrate statistically significant improved overall survival.

read article

Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop

(Amgen) Mar 3, 2017 - Results to be presented as late-breaking oral presentation; largest international trial conducted in multiple myeloma; study met primary endpoint of non-inferiority versus zoledronic acid in delaying bone complications known as skeletal-related events.

read corporate press release

CNN Profiles Black Swan Research Initiative’s Innovative iStopMM Project And Asks “Why Iceland?”

(International Myeloma Foundation) Mar 1, 2017 - The iStopMM testing in Iceland of 4,000 patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor state to myeloma, will allow researchers to look for linkages to particular family gene patterns.

read article

Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop

(The Business Journals) Mar 1, 2017 - Detailed results from phase 3 head-to-head Endeavor trial show Kyprolis significantly improved overall survival compared to Velcade® (bortezomib) in relapsed or refractory multiple myeloma patients; late-breaking results from largest international trial conducted in multiple myeloma show Xgeva was non-inferior versus zoledronic acid in delaying bone complications.

read article

Longer Survival Seen With Amgen's Kyprolis vs Velcade In Myeloma Study

(Reuters) Feb 28, 2017 - Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.

read article

First Opinion: The Power — And The Fear — Of Knowing Your Cancer Genome

(STAT Plus) Feb 23, 2017 - When it comes to cancer, all knowledge is power — even when that knowledge is scary. Knowing as much as you can about cancer lets you and your health care team act decisively in devising your treatment strategy.

read article (paid subscription required)
Next Page